[EN] METHODS OF USE FOR OPSIN BINDING LIGANDS<br/>[FR] PROCÉDÉS D'UTILISATION DE LIGANDS DE LIAISON DE L'OPSINE
申请人:BIKAM PHARMACEUTICALS INC
公开号:WO2010074746A1
公开(公告)日:2010-07-01
Methods of use of compounds of the Formula I1 II, III, IV and/or V are disclosed for treating ophthalmic conditions related to the production of toxic visual cycle products that accumulate in the eye, and are associated with reactions of the visual cycle during medical procedures that expose the eye to light, most commonly the various forms of ophthalmic surgery and stabilize the proper folding of mutant opsins. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described, along with methods of screening for new agents useful in said treatments.
Novel xanthine oxidase inhibitor studies. Part 2. Synthesis and xanthine oxidase inhibitory activities of 2-substituted 6-alkylidenehydrazino- or 6-arylmethylidenehydrazino-7H-purines and 3- and/or 5-substituted 9H-1,2,4-triazolo[3,4-i ]purines
general synthesis of 2-substituted 6-alkylidenehydrazino- or 6-arylmethylidenehydrazino-7H-purines and 3- and/or 5-substituted 9H-1,2,4-triazolo[3,4-i]purines, which were obtained by oxidative cyclisation of the corresponding 6-aldehyde hydrazones of 7H-purine, as a new class of potential xanthine oxidaseinhibitors are reported. Their inhibitory activities against bovine milk xanthine oxidase in vitro
2-取代的6-亚烷基萘并肼基或6-芳基亚甲基肼基并氨基7 H-嘌呤和3-和/或5-取代的9 H -1,2,4-三唑并[3,4- -i ]嘌呤的简便且通用的合成方法,据报道,它们是通过相应的7 H-嘌呤的6-醛的氧化环化而获得的,作为新型潜在的黄嘌呤氧化酶抑制剂。还研究了它们在体外对牛黄嘌呤氧化酶的抑制活性,一些嘌呤2和6和三唑并呋喃酮7的活性比别嘌呤醇高出几倍到几百倍。